All News
EULAR 2024 – Day 3 Report
EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.
Read ArticleImpact of regulatory warning on JAK inhibitors
The development of JAK inhibitors represents an advance for the treatment of inflammatory rheumatic diseases. However, the enthusiasm in using this target has waned since the publication of the ORAL surveillance clinical trial in 2022. Subsequently, both the FDA and EMA issued a warning on using JAKi in patients with certain risk factors, e.g., ≥65 years, at increased risk of MACE, current smoker or past smoker and at increased risk of cancer, should other alternative treatment be available. So, how has this warning impacted on JAKi development and use?
Read ArticleAurelie Najm AurelieRheumo ( View Tweet)
Peter Nash drpnash ( View Tweet)
Peter Nash drpnash ( View Tweet)
Peter Nash drpnash ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Janet Pope Janetbirdope ( View Tweet)
Links:
Janet Pope Janetbirdope ( View Tweet)
Links:
David Liew drdavidliew ( View Tweet)